These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A Focus Group Study on African American Living Donors' Treatment Preferences, Sociocultural Factors, and Health Beliefs About Apolipoprotein L1 Genetic Testing. Gordon EJ; Amórtegui D; Blancas I; Wicklund C; Friedewald J; Sharp RR Prog Transplant; 2019 Sep; 29(3):239-247. PubMed ID: 31146624 [TBL] [Abstract][Full Text] [Related]
7. Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index. Julian BA; Gaston RS; Brown WM; Reeves-Daniel AM; Israni AK; Schladt DP; Pastan SO; Mohan S; Freedman BI; Divers J Am J Transplant; 2017 Jun; 17(6):1540-1548. PubMed ID: 27862962 [TBL] [Abstract][Full Text] [Related]
8. Association of Recipient APOL1 Kidney Risk Alleles With Kidney Transplant Outcomes. Roy N; Morales-Alvarez MC; Anis KH; Goral S; Doria C; Kopp JB; Winkler CA; Feng R; Rosas SE Transplantation; 2023 Dec; 107(12):2575-2580. PubMed ID: 37527489 [TBL] [Abstract][Full Text] [Related]
9. Practical Considerations for APOL1 Genotyping in the Living Kidney Donor Evaluation. Mena-Gutierrez AM; Reeves-Daniel AM; Jay CL; Freedman BI Transplantation; 2020 Jan; 104(1):27-32. PubMed ID: 31449181 [TBL] [Abstract][Full Text] [Related]
11. The APOL1 gene and allograft survival after kidney transplantation. Reeves-Daniel AM; DePalma JA; Bleyer AJ; Rocco MV; Murea M; Adams PL; Langefeld CD; Bowden DW; Hicks PJ; Stratta RJ; Lin JJ; Kiger DF; Gautreaux MD; Divers J; Freedman BI Am J Transplant; 2011 May; 11(5):1025-30. PubMed ID: 21486385 [TBL] [Abstract][Full Text] [Related]
12. African American Living Donors' Attitudes About APOL1 Genetic Testing: A Mixed Methods Study. Gordon EJ; Amόrtegui D; Blancas I; Wicklund C; Friedewald J; Sharp RR Am J Kidney Dis; 2018 Dec; 72(6):819-833. PubMed ID: 30360961 [TBL] [Abstract][Full Text] [Related]
13. Introducing Genetic Tests With Uncertain Implications in Living Donor Kidney Transplantation: ApoL1 as a Case Study. Ross LF; Thistlethwaite JR Prog Transplant; 2016 Sep; 26(3):203-6. PubMed ID: 27302054 [TBL] [Abstract][Full Text] [Related]
14. How good is a living donor? Systematic review and meta-analysis of the effect of donor demographics on post kidney transplant outcomes. Bellini MI; Nozdrin M; Pengel L; Knight S; Papalois V J Nephrol; 2022 Apr; 35(3):807-820. PubMed ID: 35072936 [TBL] [Abstract][Full Text] [Related]
15. Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts. Santoriello D; Husain SA; De Serres SA; Bomback AS; Crew RJ; Vasilescu ER; Serban G; Campenot ES; Kiryluk K; Mohan S; Hawkins GA; Hicks PJ; Cohen DJ; Radhakrishnan J; Stokes MB; Markowitz GS; Freedman BI; D'Agati VD; Batal I Kidney Int; 2018 Dec; 94(6):1189-1198. PubMed ID: 30287079 [TBL] [Abstract][Full Text] [Related]
16. APOL1 high-risk genotypes and renal transplantation. Shah S; Shapiro R; Murphy B; Menon MC Clin Transplant; 2019 Jun; 33(6):e13582. PubMed ID: 31050035 [TBL] [Abstract][Full Text] [Related]
17. Podocyte density is reduced in kidney allografts with high-risk APOL1 genotypes at transplantation. Chen DP; Zaky ZS; Schold JD; Herlitz LC; El-Rifai R; Drawz PE; Bruggeman LA; Barisoni L; Hogan SL; Hu Y; O'Toole JF; Poggio ED; Sedor JR Clin Transplant; 2021 Apr; 35(4):e14234. PubMed ID: 33511679 [TBL] [Abstract][Full Text] [Related]
18. Transplantation With APOL1 Risk Variant Kidney May Be Associated With Lifetime Risk for Recurrence of Focal Segmental Glomerulosclerosis: A Case Report and Review of Literature. Mirza A; Kowalewska J; McCune T Transplant Proc; 2019 Nov; 51(9):3077-3079. PubMed ID: 31324484 [TBL] [Abstract][Full Text] [Related]